Artiva Biotherapeutics, Inc.
ARTV- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817241
In the last 90 days, Artiva Biotherapeutics, Inc. insiders filed 5 open-market purchases and 7 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $391.6M in total; Viking Global Investors is the only superinvestor holding it.
Superinvestors holding ARTV, Q2 2026
1 superinvestor reports holding Artiva Biotherapeutics, Inc. on Form 13F, worth $25.3M in total. Weight is Artiva Biotherapeutics, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Viking Global InvestorsAndreas Halvorsen | 0.1% | 2,604,166 | $25.3M | New |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of ARTV each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end